the hazard ratio thing finally clicked for me and I want to write it down
STEP. That is the whole post, but I will justify it. Everything else people worry about in c/orforglipron is downstream of it. Titration speed, early fullness, the endless dose arguments — most of it resolves if you sort STEP out first, and almost nobody does. I say this having got it wrong for 8 months. My eGFR was…
dropout handling matters, especially on GI-heavy populations
Which trial and what was the primary endpoint?
STEP 1 readout: 98.6% mean weight loss, absolute numbers matter. Spread around that mean is enormous.
STEP 1 readout: 98.0% mean weight loss, absolute numbers matter. Spread around that mean is enormous.
Respectfully this is a sample of one presented as a finding.
give the trial name, phase, n, and primary endpoint in the body
dropout handling matters, especially on GI-heavy populations
Yes, exactly this, and it is the bit that took me 39 weeks to accept.
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
phase 2 is not phase 3, smaller n and shorter trial
the discontinuation arms are the interesting part, not the SURMOUNT endpoints
the 24 week readout is different from the 32 week readout